Sarepta Therapeutics, Inc.
215 First Street
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy(DMD), Limb-girdle muscular dystrophy (LGMD) and CNS. The Company has close to 30 programs in development across several therapeutic modalities, including RNA, gene therapy and gene editing.
Corporate Mission Statement:
Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease.
At Sarepta, every day is another 24 hours to stand up for patients, advance technology, challenge convention and drag tomorrow into today.
Stock Symbol: SRPT
Stock Exchange: NASDAQ
685 articles with Sarepta Therapeutics, Inc.
History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient pop...
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne --
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
AcelRx is seeking $40 million to support the launch of Dsuvia and Sarepta eyes $500 million to support clinical research.
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Beta-sarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E
First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
The American University Washington College of Law and the Food and Drug Law Institute hosted a conference late last week. One of the highlights was a plenary session that featured former commissioners of the U.S. Food and Drug Administration (FDA).
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Expands Sarepta’s portfolio to as many as 14 gene therapy programs
Sarepta Therapeutics’ experimental gene-therapy treatment for Duchenne muscular dystrophy (DMD) is showing some early signs of promise. Patients who received the therapy are showing increasing signs of a muscle protein that had been missing, the company said.
Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial
Biopsy of fourth patient showed robust micro-dystrophin expression as measured by Western blot and immunohistochemistry
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene ...
9/24/2018Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company's Duchenne...
In September 2016, the U.S. FDA approved Sarepta Therapeutics’ eteplirsen, now marketed as Exondys 51, for Duchenne muscular dystrophy (DMD). And now, two years later, the European Medicines Agency (EMA) has rejected Sarepta’s application for Exondys 51.
Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
8/30/2018Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureT...
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Cambridge, Mass.-based Sarepta Therapeutics expanded its gene therapy pipeline up to 11 in an equity deal with Lacerta Therapeutics. Investing $30 million into Alachua, Florida-based Lacerta Therapeutics, Sarepta gained access to the company’s AAV-based CNS-targeted gene therapies.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...